Objectives:
Cytokine-targeted therapies continue to improve the treatment landscape of rheumatic and autoinflammatory diseases.
This symposium will focus on the evolving role of IL-1 and IL-6 pathway targeting, highlighting recent clinical evidence and
practical experience with olokizumab and goflikicept across adult and pediatric inflammatory disorders.
Experts will discuss current challenges in disease management, emerging therapeutic approaches, and the future potential of targeted cytokine inhibition in improving long-term patient care.
| Agenda - Friday 30 October | |
|---|---|
|
|
Chairperson: A/Prof Jose Paulo Lorenzo, Philippines and Prof Ekaterina Iosifovna Alekseeva, Russian Federation
|
|
1730-1745 |
Harmony Through Direct IL-6 Control: Real-World Rheumatology Insights Dr Alena Igorevna Zagrebneva, Russian Federation |
|
1745-1800 |
Restoring the Balance: Goflikicept as a Precision IL-1 Inhibitor in Familial Mediterranean Fever Prof Serdal Uğurlu, Turkiye |
|
1800-1815 |
The Art of Inflammatory Control: Strategic IL-1 and IL-6 Targeting in Pediatric Practice Prof Ekaterina Iosifovna Alekseeva, Russian Federation |
|
1815-1825 |
Closing Remarks: Q&A and Discussion Dr Alena Igorevna Zagrebneva, Russian Federation Prof Serdal Uğurlu, Turkiye Prof Ekaterina Iosifovna Alekseeva, Russian Federation |
